18F-FDG PET detects inflammatory infiltrates in spinal cord experimental autoimmune encephalomyelitis lesions

Journal of Nuclear Medicine

Volumn 53, Issue 8, 2012, Pages 1269-1276

  Buck, Dorothea ^a   Förschler, Annette ^b   Lapa, Constantin ^b   Schuster, Tibor ^c   Vollmar, Patrick ^a   Korn, Thomas ^a   Nessler, Stefan ^a   Stadelmann, Christine ^d   Drzezga, Alexander ^b   Buck, Andreas K ^b   Wester, Hans Jürgen ^b   Zimmer, Claus ^b   Krause, Bernd Joachim ^b   Hemmer, Bernhard ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

EAE; MRI; Multiple sclerosis; PET

Indexed keywords

3' FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; (18F)FLUOROETHYLTYROSINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; TYROSINE;

ALLERGIC ENCEPHALOMYELITIS; AMINO ACID TRANSPORT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CEREBELLUM; CEREBELLUM VERMIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; FEMALE; GLUCOSE UTILIZATION; HISTOPATHOLOGY; IMAGE PROCESSING; INFLAMMATORY INFILTRATE; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; SPINAL CORD; ANIMAL; IMMUNOLOGY; INFLAMMATION; PATHOLOGY; SCINTISCANNING;

ANIMALS; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FLUORODEOXYGLUCOSE F18; INFLAMMATION; POSITRON-EMISSION TOMOGRAPHY; RATS; SPINAL CORD; TYROSINE;

EID: 84864776548     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.102608     Document Type: Article

References (33)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359:1221-1231. (Pubitemid 34304266)
2. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247-269.
3. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17:210-218. (Pubitemid 46466140)
4. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008;71:129-135.
5. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology. 2010;74:2004-2015.
6. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707-717. (Pubitemid 30390191)
7. Hemmer B, Hartung HP. Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann Neurol. 2007;62:314-326. (Pubitemid 350105946)
8. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006;253:98-108. (Pubitemid 43157395)
9. Bates D. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology. 2011;76:S14-S25.
10. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain. 2002;125:2202-2212.
11. Montalban X, Tintore M, Swanton J, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology. 2010;74:427-434.
12. Bakshi R, Thompson AJ, Rocca MA, et al. MRI in multiple sclerosis: current status and future prospects. Lancet Neurol. 2008;7:615-625.
13. Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009;5:256-266.
14. Frauwirth KA, Alegre ML, Thompson CB. Induction of T cell anergy in the absence of CTLA-4/B7 interaction. J Immunol. 2000;164:2987-2993. (Pubitemid 30148957)
15. Gamelli RL, Liu H, He LK, Hofmann CA. Augmentations of glucose uptake and glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J Leukoc Biol. 1996;59:639-647. (Pubitemid 26198075)
16. Fu Y, Maianu L, Melbert BR, Garvey WT. Facilitative glucose transporter gene expression in human lymphocytes, monocytes, and macrophages: a role for GLUT isoforms 1, 3, and 5 in the immune response and foam cell formation. Blood Cells Mol Dis. 2004;32:182-190. (Pubitemid 38147716)
17. Kohm AP, Carpentier PA, Anger HA, Miller SD. Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol. 2002;169:4712-4716. (Pubitemid 35217131)
18. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336. (Pubitemid 28512118)
19. 18F]fluorothymidine. Methods. 2009;48:205-215.
20. Nair-Gill ED, Shu CJ, Radu CG, Witte ON. Non-invasive imaging of adaptive immunity using positron emission tomography. Immunol Rev. 2008;221:214-228. (Pubitemid 351230112)
21. Padma MV, Adineh M, Pugar K, et al. Functional imaging of a large demyelinating lesion. J Clin Neurosci. 2005;12:176-178. (Pubitemid 40326667)
22. 18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40:205-212.
23. Bendszus M, Ladewig G, Jestaedt L, et al. Gadofluorine M enhancement allows more sensitive detection of inflammatory CNS lesions than T2-w imaging: a quantitative MRI study. Brain. 2008;131:2341-2352.
24. Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist. 1979;6:65-70.
25. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol. 2006;24:3282-3292. (Pubitemid 46622068)
26. Radu CG, Shu CJ, Shelly SM, Phelps ME, Witte ON. Positron emission tomography with computed tomography imaging of neuroinflammation in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2007;104:1937-1942. (Pubitemid 46239882)
27. Zhang J, Cross AH, McCarthy TJ, Welch MJ. Measurement of upregulation of inducible nitric oxide synthase in the experimental autoimmune encephalomyelitis model using a positron emitting radiopharmaceutical. Nitric Oxide. 1997;1:263-267. (Pubitemid 28079404)
28. Vowinckel E, Reutens D, Becher B, et al. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci Res. 1997;50:345-353. (Pubitemid 27473649)
29. Moore GR, Leung E, MacKay AL, et al. A pathology-MRI study of the short-T2 component in formalin-fixed multiple sclerosis brain. Neurology. 2000;55:1506-1510.
30. Hasselbalch SG, Knudsen GM, Holm S, Hageman LP, Capaldo B, Paulson OB. Transport of D-glucose and 2-fluorodeoxyglucose across the blood-brain barrier in humans. J Cereb Blood Flow Metab. 1996;16:659-666. (Pubitemid 26227076)
31. 18F-FDG. J Nucl Med. 2005;46:945-952.
32. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791-3798.
33. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48:726-735.